کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1929079 | 1050443 | 2012 | 4 صفحه PDF | دانلود رایگان |

Human noroviruses are the primary cause of foodborne gastroenteritis. Potent and safe inhibitors are needed for the treatment/prophylaxis of norovirus infections. We demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Time-of-drug addition studies reveal that T-705 exerts its activity at a time-point that coincides with onset of viral RNA synthesis, which is in line with the viral polymerase as the presumed target.
► Favipiravir (T-705) is an influenza drug in clinical development.
► Favipiravir inhibits (murine) norovirus-induced CPE and viral RNA synthesis.
► Favipiravir inhibits viral replication at a time point that coincides with the onset of viral RNA synthesis.
Journal: Biochemical and Biophysical Research Communications - Volume 424, Issue 4, 10 August 2012, Pages 777–780